Immunotherapy for glioblastoma: going viral

J Bryan Iorgulescu; David A Reardon; E Antonio Chiocca; Catherine J Wu

doi:10.1038/s41591-018-0142-3

Immunotherapy for glioblastoma: going viral

Nat Med. 2018 Aug;24(8):1094-1096. doi: 10.1038/s41591-018-0142-3.

Authors

J Bryan Iorgulescu^{1

2

3}, David A Reardon^{1

2

4}, E Antonio Chiocca^{2

5}, Catherine J Wu^{6

7

8}

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Center, Boston, MA, USA.
² Harvard Medical School, Boston, MA, USA.
³ Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
⁴ Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
⁵ Department of Neurosurgery, Brigham and Women's Hospital, Dana-Farber Cancer Center, Boston, MA, USA.
⁶ Department of Medical Oncology, Dana-Farber Cancer Center, Boston, MA, USA. cwu@partners.org.
⁷ Harvard Medical School, Boston, MA, USA. cwu@partners.org.
⁸ Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. cwu@partners.org.

Abstract

Intratumoral infusion of a nonpathogenic replication-competent recombinant polio-rhinovirus chimera for recurrent glioblastoma demonstrates safety and promising preliminary treatment responses.

MeSH terms

Adult
Clinical Trials as Topic
Glioblastoma / immunology*
Glioblastoma / therapy*
Humans
Immunotherapy*
Oncolytic Virotherapy*
Survival Analysis

Abstract

MeSH terms

Grants and funding